Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
143 hedge funds and large institutions have $927M invested in Sage Therapeutics in 2016 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 72 increasing their positions, 27 reducing their positions, and 21 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 27
71% more call options, than puts
Call options by funds: $3.63M | Put options by funds: $2.12M
67% more funds holding in top 10
Funds holding in top 10: 6 → 10 (+4)
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
4% more funds holding
Funds holding: 137 → 143 (+6)
32% less capital invested
Capital invested by funds: $1.37B → $927M (-$440M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$26.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$22.2M |
| 3 |
DM
Deerfield Management
New York
|
+$18.1M |
| 4 |
VAM
Visium Asset Management
New York
|
+$17.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$19.8M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$8.92M |
| 3 |
Bank of New York Mellon
New York
|
-$7.7M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$6.75M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$5.67M |
SAGE Hedge Fund Activity: Q1 2016 in Review
143 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q1 2016, worth a combined $927M — down 32% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SAGE positions and 21 closed out — a net gain of 8 holders — while 72 added to existing stakes and 27 trimmed.
The largest buyer was OppenheimerFunds, opening a new position worth an estimated $26.4M. The largest seller was Lord, Abbett & Co, cutting an estimated $19.8M.
- 143 institutional investors held Sage Therapeutics (SAGE) as of Q1 2016, up from 137 in Q4 2015.
- Funds reported $927M of Sage Therapeutics stock for Q1 2016, down 32% quarter-over-quarter.
- 29 funds opened new Sage Therapeutics positions in Q1 2016 and 21 closed out, a net change of +8 holders.
- The largest Sage Therapeutics buyer in Q1 2016 was OppenheimerFunds, an estimated $26.4M added.
- The largest Sage Therapeutics seller in Q1 2016 was Lord, Abbett & Co, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2016.